Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Northern Registry Centre, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
BMJ Open. 2022 Dec 20;12(12):e064898. doi: 10.1136/bmjopen-2022-064898.
We constructed Bladder Cancer Data Base Sweden (BladderBaSe) 2.0 to expand studies in BladderBaSe on incidence, treatment outcomes, side effects, survival and health economic aspects of men and women with cancer in the urinary bladder, upper tract urothelial carcinoma (UTUC) (renal pelvis and ureter) and urethral carcinoma.
BladderBaSe 2.0 includes 53 298 patients with cancer in the urinary bladder, diagnosed from 1 January 1997 to 31 December 2019, and 961 patients with UTUC in the renal pelvis and 792 in the ureter, and 146 patients with urethral urothelial carcinoma, diagnosed from 1 January 2015 to 31 December 2019, and in total 275 816 participants in reference groups, free of cancer in the urinary tract, matched 1:5 on sex, age and county.
To date, 18 published studies based on data from the BladderBaSe have investigated calendar time trends in survival; impact of gender, socioeconomic factors, tumour aggressiveness and hospital volume for radical cystectomy on prognosis; survival after radical cystectomy compared with radical radiotherapy; risk factors for complications and side effects after radical cystectomy such as thromboembolism, strictures of ureteroenterostomies and incisional hernia.
The BladderBaSe initiators are currently investigating gender-dependent detection delays due to urinary tract infections; survival after non-muscle invasive bladder cancer with respect to the number of transurethral resections; short-term outcomes comparing open and robot-assisted radical cystectomy; studies on risk for intravesical recurrence after different diagnostic measures in UTUC, and suicide risk after bladder cancer diagnosis. The BladderBaSe project group is open for collaborations with national and international colleagues.
我们构建了膀胱癌数据库瑞典（BladderBaSe）2.0，以扩展对膀胱癌、上尿路尿路上皮癌（肾盂和输尿管）和尿道癌患者发病率、治疗结果、副作用、生存和健康经济学方面的研究。
BladderBaSe 2.0 包含 53298 名男性和女性膀胱癌患者，诊断时间为 1997 年 1 月 1 日至 2019 年 12 月 31 日；961 名肾盂和 792 名输尿管尿路上皮癌患者，以及 146 名尿道尿路上皮癌患者，诊断时间为 2015 年 1 月 1 日至 2019 年 12 月 31 日；总共 275816 名参考组患者，无尿路癌，按性别、年龄和县匹配 1:5。
迄今为止，基于 BladderBaSe 数据的 18 项已发表研究调查了生存的日历时间趋势；性别、社会经济因素、肿瘤侵袭性和根治性膀胱切除术的医院量对预后的影响；根治性膀胱切除术与根治性放疗的生存比较；根治性膀胱切除术后血栓栓塞、输尿管肠吻合口狭窄和切口疝等并发症和副作用的危险因素。
BladderBaSe 的发起者目前正在调查由于尿路感染导致的性别依赖性检测延迟；非肌肉浸润性膀胱癌与经尿道切除术次数的关系；比较开放和机器人辅助根治性膀胱切除术的短期结果；不同诊断措施在肾盂癌中的肿瘤内复发风险以及膀胱癌诊断后的自杀风险。BladderBaSe 项目组对与国内外同行的合作持开放态度。
